Dexcom ( NASDAQ:DXCM ) stock ended Friday's trading session on a rough slate despite the company's first-quarter beat and boosted sales guidance. Sales guidance, however, was light at the midpoint and Dexcom ( NASDAQ:DXCM ) stock plummeted 10%, closing at 124.34. easily boycotting a recent buy point at 132.03 out of a flat base. Some analysts noted that the...
Analyzing the options chain and the chart patterns of DXCM DexCom prior to the earnings report this week, I would consider purchasing the 137usd strike price Calls with an expiration date of 2024-5-3, for a premium of approximately $5.95. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Fundamentals: Develops glucose monitoring systems. This stock meets 80% of my parameters. I wouldn't have considered it if the earnings were not above 20%. I do not like the stability of the earnings and I do not like the trajectory of the earnings, though. However, I do like the accelerating sales. Funds and quality funds began to grow into this stock again. I...
══════════════════════════════ Since 2014, my markets approach is to spot trading opportunities based solely on the development of CLASSICAL CHART PATTERNS 🤝Let’s learn and grow together 🤝 ══════════════════════════════ Hello Traders ✌ After a careful consideration I came to the conclusion that: - it is crucial to be quick in alerting you with all the...
On 2/8/2024, DexCom (DXCM) reported earnings of $0.50 per share on revenue of $1.03 billion for the fourth quarter ended December 2023. The consensus earnings estimate was $0.43 per share on revenue of $1.02 billion.
DXCM had been essentially a range bound stock in the past 3 years, forming what is potentially a long term head & shoulders formation (bearish if break down). However, it looks like the odds of breaking down has diminished with a bullish monthly pin bar now forming after finding support at its 88.6% fib retracement (imperfect double bottom). The stock is still...
DexCom, Inc. DXCM reported third-quarter 2023 adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 22 cents by 47.1%. The company reported earnings of 28 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 29 cents, up from the year-ago quarter’s figure of 24 cents. Shares of DexCom rose...
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM), which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. This medical device company has an established record of topping earnings estimates,...
When price clears: 125.55 With daily volume greater than: 5.623M Target: 149 area Stop: Depending on your risk tolerance; 117.75 gets you 3/1 Risk/Reward. Resistance: 136.76 area This swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade...
Triple Inside weeks here , tight range , looking for a break above prev days close , 126.71 Long above 127.25 , Risk at 126.35 For a possible move into 131! NASDAQ:DXCM Possible swing into 134 if we break hod!
NASDAQ:DXCM Breakout swing trade entry. Forming a ascending triangle after breakout
would be looking for a low risk entry this week or next maybe..
Company: Dexcom Inc. Ticker: DXCM Exchange: NASDAQ Sector: Health Technology Introduction: Our technical analysis today concentrates on Dexcom Inc. (DXCM), a prominent name in the Health Technology sector, listed on the NASDAQ. A potential Cup and Handle pattern, serving as a reversal formation, has been forming on the weekly chart, suggesting a promising...
Price appears to be bound by 2 trendlines is a horizontal trading zone. Rectangles like many patterns are neutral until broken. The top line is R and the bottom line is S. No recommendation/Bearish Harami so far today Day Range 113.05 115.47 EPS (FWD) 1.04 PE (FWD) 109.94 Div Rate (TTM) - Yield (TTM) - Short Interest 3.38%
$DXCM up on volume. Looking for a retest here before entry. Still has a couple highs to break through as well as a support zone but the R/R is good.
Diabetes company DexCom has consolidated for about four months, and now it could be trying to move again. The first pattern on today’s chart is the bullish candle on February 10 after earnings beat estimates. It followed a similar rally on October 28, suggesting that investors are pleased with its fundamental performance. The earnings surge established DXCM...
$DXCM pullback buy potentially triggers tomorrow morning. Less than 2% stop loss to figure out if you are wrong. They don't get any mush low risk setups than this.
I would place a limit buy order if it retest downwards. Earnings on Thursday and common positive outlook by analysts.